Exelixis

FDA oncology advisory committee to weigh Exelixis' Cabometyx in neuroendocrine tumors
Fierce Pharma
Sun, 12/1/24 - 11:52 am
Exelixis
Cabometyx
neuroendocrine tumors
FDA
Exelixis drops tissue factor-targeting ADC after deciding it's no match for Tivdak
Fierce Biotech
Wed, 08/7/24 - 11:19 am
Exelixis
antibody-drug conjugate
tissue factor
XB002
Tivdak
Pfizer
Genmab
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
BioSpace
Fri, 01/12/24 - 09:40 am
Bioinvent
Exelixis
immuno-oncology
Exelixis lays off 175 employees in refocus on ‘emerging pipeline’
Fierce Biotech
Mon, 01/8/24 - 11:39 am
Exelixis
layoffs
Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says
Fierce Pharma
Thu, 08/24/23 - 08:37 pm
Carbometyx
Exelixis
clinical trials
neuroendocrine tumors
Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial
BioSpace
Wed, 08/23/23 - 10:12 am
Eli Lilly
Retevmo
thyroid cancer
medullary thyroid cancer
clinical trials
Exelixis
Capometyx
Sanofi
Caprelsa
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Mon, 08/21/23 - 10:02 am
Exelixis
Ipsen
Carbometyx
prostate cancer
Exelixis, Teva settle Cabometyx patent litigation with 2031 generic license
Fierce Pharma
Mon, 07/24/23 - 11:32 am
Exelixis
Teva Pharmaceutical
patents
legal
Cabometyx
cancer
Exelixis Advances Board Refreshment Plan
Businesswire
Thu, 04/13/23 - 10:23 pm
Exelixis
Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure
BioSpace
Fri, 03/3/23 - 12:01 pm
Roche
Exelixis
renal cell carcinoma
Tecentriq
Cabometyx
clinical trials
Combo of Roche's Tecentriq and Exelixis' Cabometyx fails another trial, this time in lung cancer
Fierce Pharma
Sun, 12/11/22 - 01:20 pm
Roche
Tecentriq
Exelixis
Cabometyx
clinical trials
non small cell lung cancer
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Fri, 12/9/22 - 10:39 am
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent
BioSpace
Thu, 11/3/22 - 07:34 pm
Exelixis
Catalent
antibody-drug conjugate
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Mon, 07/11/22 - 05:48 pm
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
ADC Space Continues to Thrive with Four More Companies Linking Up
BioSpace
Thu, 06/16/22 - 10:30 am
antibody-drug conjugate
Exelixis
Bioinvent
Oxford BioTherapeutics
Immunogen
Exelixis taps into cancer antibody discoverer out of Sweden
Endpoints
Thu, 06/16/22 - 10:28 am
Exelixis
Bioinvent
cancer
Sweden
immuno-oncology
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Endpoints
Tue, 03/15/22 - 10:39 am
Exelixis
Cabometyx
liver cancer
clinical trials
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Novartis
M&A
Roche
Sandoz
Aurinia Pharmaceuticals
Alnylam
Exelixis
Incyte
Eisai
Genmab
Exelixis pulls a surprise win in thyroid cancer just days ahead of final Cabometyx readout
Endpoints
Mon, 09/20/21 - 11:57 am
ESMO
Exelixis
thyroid cancer
Cabometyx
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
Fierce Pharma
Sat, 09/18/21 - 08:27 pm
ESMO
Exelixis
Cabometyx
Roche
Tecentriq
clinical trials
prostate cancer

Pages